Metaplastic carcinoma of the breast is an uncommon type of malignancy that is aggressive but can mimic other benign breast neoplastic processes on imaging. We present a case of a young female patient who presented with a rapidly progressing metaplastic carcinoma with osteoclastic giant cells subtype. There have been only very rare published reports of this pathologic subtype of metaplastic carcinoma containing osteoclastic giant cells.
CASE REPORT
A 29-year old premenopausal BRCA negative female, without significant past medical history or family history of breast cancer and history of prior fibroadenoma, presented clinically with a rapidly enlarging, tender, palpable right breast mass at the 9:00 position over a period of 1 month. Due to the patient's young age, mammographic imaging was deferred and targeted sonographic exam was instead performed for initial evaluation.
Sonographic evaluation demonstrated a 1.8x1.2x1.6cm oval, circumscribed, solid mass without increased internal flow corresponding to the palpable abnormality ( Figure 1 ). Subsequent ultrasound-guided core needle biopsy was performed. Pathology demonstrated poorly differentiated carcinoma with sarcomatoid features and osteoclast-like giant cells (Figure 2 ). Immunohistochemical staining showed positivity for epithelial membrane antigen (EMA). The presence of EMA confirms carcinoma cells, in this case either poorly differentiated or sarcomatoid carcinoma suggestive of metaplastic carcinoma, and not cells of a sarcoma or phyllodes tumor.
Immunohistochemistry (IHC) was negative for estrogen receptor (ER), negative for progesterone receptor (PR), and negative for HER2/neu expression. The KI-67 labeling index was 60%.
A breast magnetic resonance image (MRI) obtained approximately 2 weeks after initial diagnosis demonstrated interval increase in size of the mass to 4.6x3.1x3.7cm. Features suggestive of a complex mass with enhancing septations, areas of short tau inversion recovery (STIR) hyperintensity and T1 isointensity. Rapid washout kinetics was also demonstrated (Figure 3 ).
The patient elected to undergo in vitro fertilization procedure after her diagnosis because of her nongravid history and planned upcoming aggressive treatment, which postponed neoadjuvant chemotherapy. A follow-up breast ultrasound performed 6 weeks after initial diagnosis prior to chemotherapy treatment showed further interval increase in size of the mass, appearing as a complex solid and cystic mass replacing almost the entirety of the lateral breast parenchyma measuring at least 10x5x4cm (Figure 4) . A fluid component was noted to extend from 2-6:00 position. On physical exam, there was discoloration of nearly the entire breast with a red/purplish outgrowth into the skin at the 7-8:00 position (Figure 4 ). Due to marked tenderness, mass effect and tension caused by this rapidly enlarging mass, ultrasound-guided aspiration was performed ( Figure 5 ) for symptomatic relief. Cytology of the aspirated fluid demonstrated primarily blood with scattered poorly differentiated sarcomatous-like cells and osteoclast-like giant cells. Gram stain and culture demonstrated no growth or bacteria. Cytology findings were confirmatory of the initial core biopsy histology, with possible differential including poorly differentiated invasive mammary carcinoma with osteoclast-like giant cells.
After completion of her in vitro fertilization egg retrieval, the patient then underwent neoadjuvant chemotherapy with 4 cycles of dose-dense doxorubicin-cyclophosphamide (AC), completed at 6 months post-initial diagnosis. Postchemotherapy breast MRI (Figure 6 ) demonstrated decrease in mass size to 3.0x2.5x2.7cm, and no detectable enhancement. She subsequently underwent right breast modified radical mastectomy and left simple mastectomy, with final pathology demonstrating a right breast 3.0 cm necrotic tumor with no residual carcinoma cells (Figure 7 ). Twenty-six axillary lymph nodes and one intramammary lymph node were negative for metastatic carcinoma. She also then underwent adjuvant external beam radiation therapy consisting of 5000 cGy in 25 fractions with an electron patch to the right chest wall.
At the most recent follow-up 2 years post-diagnosis, she is doing well with no evidence of recurrence to date. She had minor residual intermittent pain in her right chest wall that is now mostly improved. She is also currently pregnant and doing well in her first trimester. MPC spreads by hematologic rather than lymphatic routes of metastasis, and usually presents as a locally aggressive mass without nodal involvement at time of detection [1] .
Etiology & Demographics

Clinical & Imaging findings
Clinically, patients frequently present with a rapidly growing, relatively large breast mass [1].
Mammographically, MPC presents as a very dense noncalcified mass with variable shapes and margins, but is most commonly oval and circumscribed [4-6].
Sonographically, it most often demonstrates an irregular shape, microlobulated margin, complex echogenicity, and parallel orientation [5] . MPCs often demonstrate posterior acoustic enhancement in contrast to the posterior acoustic shadowing that is more often seen with invasive ductal carcinomas [4] . It can often mimic a benign mass such as a complicated cyst or fibroadenoma in its early stages [7] . On magnetic resonance imaging, MPC may present as a round to lobulated mass with smooth margins with T2 hyperintense signal due to necrosis and cystic degeneration, rim-like enhancement, and type III washout kinetics, corresponding to the enhancing peripheral portion of the mass [5] .
Treatment & Prognosis
MPC is an aggressive form of breast cancer with worse prognosis compared to most breast cancers. It has a high incidence of local recurrence and is therefore more aggressively treated [8] .
Some predictors of poorer outcome include presence of skin invasion, presentation at age less than 39 years of age, and presence of squamous cell carcinoma in the lymph nodes [9] . Our patient presented with 2 of these 3 predictors, suggesting worse outcome.
The reported 5-year survival rate for patients with metaplastic carcinoma with OGC is 68%, which is less than the estimated 95% for invasive ductal carcinoma without lymph node involvement and 96% for invasive ductal carcinoma with occult lymph node metastasis [10]. 
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Current treatment commonly involves modified radical mastectomy, adjuvant chemotherapy and postoperative radiotherapy [11] .
Differential Diagnosis
Invasive ductal carcinoma-NOS Invasive ductal carcinoma -NOS is the most common type of breast malignancy. Characteristic imaging features of IDC include irregular shape and spiculated margins, pleomorphic calcifications, and posterior acoustic shadowing. These characteristics are not common in MPC [4] . MPC presents with larger tumor size, less nodal involvement, higher tumor grade, and hormone receptor negativity compared to IDC. Patients with MPC are treated more aggressively than IDC (more often with mastectomy and chemotherapy) because of a higher stage at presentation [1]. Sarcoma Breast sarcomas are neoplasms of stromal origin, that comprise <1% of breast malignancies. Similar to MPC, they present clinically as aggressive rapidly enlarging masses. They appear as large oval dense masses on mammography, and as oval complex solid and cystic masses with posterior acoustic enhancement on ultrasound, like MPC. However, they can sometimes show coarse calcification on mammography and tend to be hypervascular on ultrasound, which are not as commonly seen with MPCs. On MRI, they demonstrate heterogeneous enhancement, T2 hyperintensity, with rapid washout type III kinetics [11, 12] . Fibroadenoma A fibroadenoma is a benign fibroepithelial tumor composed of stromal and epithelial elements. It is the most common breast mass in women under 35 years old, with mean age at diagnosis of 30 years old [13] . It often presents on physical exam as a mobile, painless, firm rubbery mass. As mentioned, fibroadenomas can mimic the early stages of MPC. However, unlike MPC, they do not rapidly enlarge. Their mean diameter enlargement typically is less than 20% over 6 months [14] .
Typical imaging findings on mammography are of an oval circumscribed mass, similar to MPC. Some can contain coarse popcorn or heterogeneous calcifications, which MPCs do not typically demonstrate. Ultrasound features include a circumscribed oval hypoechoic or isoechoic mass, like MPCs. Unlike MPCs, they are most often homogeneous, and do not demonstrate complex or cystic components. They often do not demonstrate increased internal vascularity on Doppler, but sometime peripheral vessels can be seen [15] . On MRI, they often present as an oval circumscribed enhancing mass [16] . Some can demonstrate dark internal septations. They are often T2 or STIR hyperintense due to their myxoid components.
Phyllodes
Phyllodes tumors are fibroepithelial neoplasms. Imaging, clinical, and pathologic differentiation from the more common benign fibroadenomas can be difficult [16, 17] .
While fibroadenomas can mimic the early stages of MPC, phyllodes can mimic the counterpart later stages of MPC. Similar to MPC, they often clinically present as a rapidly enlarging circumscribed mass [18] . Unlike MPC, the majority are pathologically benign (although they can be locally aggressive), with a minority pathologically borderline or malignant.
Phyllodes can present similarly to MPC on mammogram and ultrasound [19] . On mammography, they present as a dense round or oval mass with mostly circumscribed margins. Sonographic imaging findings are an oval or round mass with variable posterior acoustic features and increased vascularity, sometimes demonstrating cystic spaces. MRI findings can also be similar to that of a MPC demonstrating a rapidly enhancing lobulated mass with T2 hyperintensity [19, 20] . However, unlike MPC, type III washout kinetics is only seen in 33% and dark internal septations can often be seen. Cystic spaces on MRI can also be seen in phyllodes like MPC, more characteristic in the less common malignant type [19, 20] .
Complicated cyst
Complicated cysts are benign breast cysts filled with internal debris composed of proteinaceous, fatty, or cellular (blood or inflammatory) components [21]. They do not contain any solid component, but sonographic features can sometimes be difficult to differentiate from a solid mass on ultrasound. They present as an oval circumscribed mass with imperceptible wall, posterior acoustic enhancement, lack of internal vascularity, and homogeneous low-level internal echoes. Differentiating sonographic characteristics that help diagnose a complicated cyst rather than a solid hypoechoic mass are features of mobile internal debris, or a fluid-debris level that shifts with positioning. [22] On mammography, they present as an oval or round circumscribed mass. Unlike solid masses, they can wax and wane in size over time [22] .
MRI features are of an oval or round smoothly marginated mass that does not demonstrate enhancement. They often demonstrate T1 hyperintensity when they contain internal proteinaceous , hematologic, or fatty content. They are mostly T2 and STIR hyperintense due to fluid content, but some can also be T2 hypointense when containing blood or proteinaceous contents [22] .
Metaplastic breast carcinoma is a rare form of breast cancer that can mimic benign processes such as a complicated cyst or fibroadenoma on imaging in its early stages, commonly presenting as a small circumscribed oval mass. But it is an aggressive malignancy that rapidly evolves on imaging into a large complex cystic and solid mass with worse prognosis than invasive ductal carcinoma, and is treated aggressively. Figure 6c ). TECHNIQUE a) axial T1 fat-saturated post-contrast image, 1.5T MRI, 1.6mm slice thickness, TR 5.5, TE 2.6, 15ml IV omniscan at 90 seconds post contrast administration b) sagittal reformatted T1 fat-saturated post-contrast image, 1.5T MRI, 0.74mm slice thickness, TR 5.5, TE 2.6 c) axial T1 subtraction with overlying angiomap, T1 fat-saturated 90 second post-contrast administration axial image subtracted by T1 fat-saturated pre-contrast administration axial image, 1.5T MRI, 1.6mm slice thickness, superimposed with kinetics angiomap of red-Type III rapid washout kinetics, yellow -Type II rapid plateau kinetics, blue -Type I rapid persistent kinetics. d) axial T1 fat-saturated pre-contrast image, 1.5T MRI 1.6mm slice thickness, TR 5.5, TE 2.6 e) axial short tau inversion recovery (STIR) image, 1.5T MRI, 3.2mm slice thickness, TR 3000, TE 66.7 
